References
- Farhadi A, Banan A, Fields J, Keshavarzian A. Intestinal barrier, an interface between health and disease. Gastroenterol. Hepatol.18(5), 479–497 (2003).
- Piche T, Barbara G, Aubert P et al. Impaired intestinal barrier integrity in the colon of irritable bowel syndrome patients, involvements of soluble mediators. Gut, DOI 0: gut.2007.140806v1 (2008) (Epub ahead of print).
- Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu. Rev. Immunol.20, 495–549 (2002).
- Annunziato F, Cosmi L, Santarlasci V et al. Phenotypic and functional features of human Th17 cells. J. Exp. Med.204, 1849–1861 (2007).
- Fuss IJ, Heller F, Borivant M et al. Non-classical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest.113, 1490–1497 (2004).
- McFarland L. State-of-the-art of irritable bowel syndrome and inflammatory bowel research in 2008. World J. Gastroenterol.14(17), 2625–2629 (2008).
- Bentley E, Jenkins D, Campbell F et al. How could pathologists improve the initial diagnosis of colitis? Evidence from an international workshop. J. Clin. Pathol.55, 955–960 (2002).
- Geboes K, Colombel JF, Greenstein A et al. Indeterminate colitis: a review of the concept – what’s in a name? Inflamm. Bowel Dis.14(6), 850–857 (2008).
- Satsangi J, Silverberg MS, Vermeire S et al. The Montreal classification of inflammatory bowel disease, controversies, consensus and implications. Gut55, 749–753 (2006).
- Meucci G. What is the incidence, prevalence, and natural history of indeterminate colitis? Inflamm. Bowel Dis.14(S2), S159–S160 (2008).
- Schreiber S, Rosenstiel P, Albrecht M et al. Genetics of Crohn’s disease, an archetypal inflammatory barrier disease. Nat. Rev. Genet.6, 376–388 (2005).
- Economou M, Trikalinus TA, Loizou KT et al. Differential effects of NOD2 variants on Crohn’s disease risk and phenotype in diverse populations, a metaanalysis. Am. J. Gastroenterol.99, 2393–2404 (2004).
- Ecounomou M, Pappas G. New global map of Crohn’s disease, genetic, environmetal, and socioeconomic correlations. Inflamm. Bowel Dis.14, 709–720 (2007).
- Gaya DR, Russel RK, Nimmo ER et al. New genes in inflammatory bowel disease, lessons for complex diseases? Lancet367, 1271–1284 (2006).
- Cho J, Weaver C. The genetics of inflammatory bowel disease. Gastroenterology133, 1327–1339 (2007).
- Kane S. What are the minimal requirements for a diagnosis of inflammatory bowel disease? Inflamm. Bowel Dis.14(S2), S148–S149 (2008).
- Joossens S, Reinisch W, Vermeire S et al. The value of serological markers in indeterminate colitis, a prospective follow-up study. Gastroenterology122(5), 1242–1247 (2002).
- Mow WS, Vasiliauskas EA, Lin YC et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology126(2), 414–424 (2004).
- Dubinsky MC, Lin YC, Dutridge D et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease, immune responses predict disease progression. Am. J. Gastroenterol.101(2), 360–367 (2006).
- Bunn SK, Bisset WM, Main MJ et al. Fecal calprotectin, validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr.33, 14–22 (2001).
- Parsi MA, Shen B, Achkar JP et al. Fetal lactoferrin for diagnosis of symptomatic patients with ileal pouch-anal anastomosis. Gastroenterology126, 1280–1286 (2004).
- Johnson MW, Maestranzi S, Duffy AM et al. Faecal calprotectin: a noninvasive diagnostic tool and marker of severity in pouchitis. Eur. J. Gastroenterol. Hepatol.20, 174–179 (2008).
- Costa F, Mumolo MG, Cecarelli L et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut54(3), 364–368 (2005).
- Diekgräfe BK, Stenson WF, Korzenik JR et al. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol. Genomics4, 1–11 (2000).
- Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn’s disease, distinctive gene expression profiles and novel suceptability candidate genes. Hum. Mol. Gen.10(5), 445–456 (2001).
- Dooley TP, Curto EV, Reddy SP et al. Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs. Inflamm. Bowel Dis.10(1), 1–14 (2004).
- Langmann T, Moehle C, Maurer R et al. Loss of detoxification in inflammatory bowel disease, dysregulation of pregnane X receptor target genes. Gastroenterology127, 26–40 (2004).
- Costello MC, Mah N, Häsler R et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med.2(8), e199 (2005).
- von Stein O. Isolation of differentially expressed genes through subtractive suppression hybridization. Methods Mol. Biol.175, 263–278 (2001).
- von Stein P, Lofberg R, Kuznetsov NV et al. Multigene analysis can discriminate ulcerative colitis, Crohn’s disease and irritable bowel syndrome. Gastroenterology134, 1869–1881 (2008).